Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 8-9, Août-Septembre 2009
Page(s) 719 - 726
Section M/S revues
DOI https://doi.org/10.1051/medsci/2009258-9719
Publié en ligne 15 août 2009
  1. Smith W. The structural and functional plasticity of influenza virus. Lancet 1951; 1 : 885–91. [Google Scholar]
  2. Nguyen-Van-Tam JS, Hampson AW. The epidemiology and clinical impact of pandemic influenza. Vaccine 2003; 21 : 1762–8. [Google Scholar]
  3. Bean WJ, Schell M, Katz J, et al. Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts. J Virol 1992; 66 : 1129–38. [Google Scholar]
  4. Treanor J, Kawaoka Y, Miller R, Webster RG, Murphy B. Nucleotide sequence of the avian influenza A/Mallard/NY/6750/78 virus polymerase genes. Virus Res 1989; 14 : 257–69. [Google Scholar]
  5. Kawaoka Y, Krauss S, Webster RG. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 1989; 63 : 4603–8. [Google Scholar]
  6. Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009 (online). [Google Scholar]
  7. Peiris JS, de Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 2007; 20 : 243–67. [Google Scholar]
  8. Tam JS. Influenza A (H5N1) in Hong Kong: an overview. Vaccine 2002; 20 (suppl 2) : S77–81. [Google Scholar]
  9. Tran TH, Nguyen TL, Nguyen TD, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004; 350 : 1179–88. [Google Scholar]
  10. Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 2006; 355 : 2186–94. [Google Scholar]
  11. Smallman-Raynor M, Cliff AD. Avian influenza A (H5N1) age distribution in humans. Emerg Infect Dis 2007; 13 : 510–2. [Google Scholar]
  12. Novel swine-origin influenza A (H1N1) virus investigation team. Emergence of a novel swine-origin influenza A (H1N1) Virus in Humans. N Engl J Med 2009 (online). [Google Scholar]
  13. Treanor JJ. Influenza virus. In : Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett’s. Principles and practice of infectious diseases, 6th ed. Philadelphia : Elsevier Churchill Livingstone,2005 : 2060–78. [Google Scholar]
  14. Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982; 4 : 25–44. [Google Scholar]
  15. Poland GA, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. Vaccine 2008 (suppl 4) : D35–40. [Google Scholar]
  16. Fiore AE, Shay DK, Haber P, et al. Prevention and control of influenza. Recommendations of the advisory committee on immunization practices (ACIP), 2007. MMWR Recomm Rep 2007;56 (RR-6) : 1–54. [Google Scholar]
  17. Hehme N, Engelmann H, Kuenzel W, et al. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004; 103 : 163–71. [Google Scholar]
  18. Stephenson I, Wood JM, Nicholson KG, et al. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004; 103 : 91–5. [Google Scholar]
  19. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2005; 11 : 1515–21. [Google Scholar]
  20. Al-Azemi A, Bahl J, Al-Zenki S, et al. Avian influenza A virus (H5N1) outbreaks, Kuwait, 2007. Emerg Infect Dis 2008; 14 : 958–61. [Google Scholar]
  21. Smith GJ, Fan XH, Wang J, et al. Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci USA 2006; 103 : 16936–41. [Google Scholar]
  22. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004; 25 : 98–104. [Google Scholar]
  23. Fedson DS, Dunnill P. From scarcity to abundance: pandemic vaccines and other agents for have not countries. J Public Health Policy 2007; 28 : 322–40. [Google Scholar]
  24. Leroux-Roels I, Leourx-Roels G. Current status and progress of prepandemic and pandemic influenza vaccine developement. Expert Rev Vaccines 2009; 8 : 401–23. [Google Scholar]
  25. Kiey MP, Subbarao K. The pandemic influenza vaccine challenge. Vaccine 2008; 26S (suppl 4) : D3-D4. [Google Scholar]
  26. Kenney RT, Frech SA, Muenz LR, et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351 : 2295–301. [Google Scholar]
  27. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004 25 ; 351 : 2286–94. [Google Scholar]
  28. Jefferson TO, Rivetti D, Di Pietrantoni C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007; 2 : CD001269. [Google Scholar]
  29. Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354 : 1343–51. [Google Scholar]
  30. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367 : 1657–64. [Google Scholar]
  31. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368 : 991–7. [Google Scholar]
  32. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370 : 580–9. [Google Scholar]
  33. Levie K, Leroux-Roels I, Hoppenbrouwers K, et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008 : 642–9. [Google Scholar]
  34. Wu J, Fang HH, Chen JT, et al. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 2009; 8 : 1087–95. [Google Scholar]
  35. Leroux-Roels I, Benrhard R, Gerard P, et al. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008; 3 : e1665. [Google Scholar]
  36. Suguitan AL Jr, McAuliffe J, Mills KL, et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006; 3 : e360. [Google Scholar]
  37. Laddy DJ, Yan J, Corbitt N, et al. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 2007; 25 : 2984–9. [Google Scholar]
  38. Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191 : 1210–5. [Google Scholar]
  39. Mozdzanowska K, Zharikova D, Cudic M, et al. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J 2007; 4 : 118. [Google Scholar]
  40. Zharikova D, Mozdzanowska K, Feng J, et al. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 2005; 79 : 6644–54. [Google Scholar]
  41. Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature 2006; 442 : 448–52. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.